AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 0.23 |
Market Cap | 42.44M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -80.39 |
PE Ratio (ttm) | 0 |
Forward PE | n/a |
Analyst | Strong Buy |
Ask | 0.23 |
Volume | 45,654,981 |
Avg. Volume (20D) | 106,750,662 |
Open | 0.26 |
Previous Close | 0.26 |
Day's Range | 0.23 - 0.26 |
52-Week Range | 0.12 - 12.48 |
Beta | undefined |
About TNXP
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, auto...
Analyst Forecast
According to 2 analyst ratings, the average rating for TNXP stock is "Strong Buy." The 12-month stock price forecast is $53.5, which is an increase of 23457.90% from the latest price.
Next Earnings Release
Analysts project revenue of $3.40M, reflecting a -10.03% YoY shrinking and earnings per share of -2.97, making a -89.21% decrease YoY.
7 months ago · investorplace.com
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024As the main stock indices like the S&P 500 and Nasdaq continue to climb, penny stocks are becoming attractive for those seeking significant returns. Despite their reputation for extreme price fluctuat...
1 year ago · proactiveinvestors.com
Tonix Pharmaceuticals expects topline results from migraine prevention study in DecemberTonix Pharmaceuticals (NASDAQ:TNXP) said it expects to receive the topline results from its 88-patient Phase 2 PREVENTION study of its investigation drug TNX-1900 for the prevention of migraine headac...